



## **Aclaris Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018**

October 29, 2018

WAYNE, Pa., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, will report financial results for third quarter 2018 on Tuesday, November 6, 2018 after U.S. financial markets close.

Management will conduct a conference call at 5:00 PM ET that day to discuss the Company's financial results and provide a general business update. A live webcast of the event can be accessed on the Events and Presentations page on the Investors section of the Aclaris website at <http://www.aclaristx.com/events-and-webcasts>. A replay of the webcast will be archived on the Aclaris website following the event.

To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference **conference ID 7694929** prior to the start of the call.

### **About Aclaris Therapeutics, Inc.**

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology, and immunology. Aclaris' focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit [www.aclaristx.com](http://www.aclaristx.com) and follow Aclaris on LinkedIn.

Aclaris Contact  
Michael Tung, M.D.  
Senior Vice President  
Corporate Strategy/Investor Relations  
484-329-2140  
[mtung@aclariastx.com](mailto:mtung@aclariastx.com)

Media Contact  
Sheila Kennedy  
Vice President, Corporate Communications  
484-321-5559  
[media@aclariastx.com](mailto:media@aclariastx.com)



Source: Aclaris Therapeutics, Inc.